Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

• Tian Zhang,
• Filippo de Braud,
• Taito Esaki,
• Wallace Akerley,
• Chrisann Kyi,
• Richard D Carvajal,
• Daniel Gusenleitner,
• Patrick Schöffski,
• Miguel Martin,
• David S Hong,
• Amy Prawira,
• Jürgen Krauß,
• Nidhi Patel,
• Rina Hui,
• Andrew Weickhardt,
• Niladri Roy Chowdhury,
• Daniel S W Tan,
• María Ochoa-de-Olza,
• John Sarantopoulos,
• Ross A Soo,
• Michela Maur,
• Barbara Deschler-Baier,
• Allen Lau,
• Tanay S Samant,
• Tyler Longmire,
• Catherine A Sabatos-Peyton,
• Radha Ramesh,
• Tiancen Hu,
• Ana Carion,
• Padmaja Yerramilli-Rao,
• Vasileios Askoxylakis,
• Eunice L Kwak

Affiliations

Tian Zhang

Department of Medicine, Center for Prostate & Urologic Cancers, Duke Cancer Institute, Durham, North Carolina, USA

Filippo de Braud

Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Taito Esaki

Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Wallace Akerley

Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA

Chrisann Kyi

Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Richard D Carvajal

Columbia University Irving Medical Center, New York City, New York, USA

Daniel Gusenleitner

Aff2 0000 0001 2106 9910grid.65499.37Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School Boston MA USA

Patrick Schöffski

Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

Miguel Martin

1 Medical Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain

David S Hong

Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA

Amy Prawira

Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital, Sidney, New South Wales, Australia

Jürgen Krauß

Department of Medical Oncology, National Center of Tumor Diseases, Heidelberg, Baden-Württemberg, Germany

Nidhi Patel

3 MS3, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA

Rina Hui

Medical Oncology, Westmead Hospital, Westmead, New South Wales, Australia

Andrew Weickhardt

10Olivia Newton-John Cancer Wellness and Res, Heidelberg, VT, Australia

Niladri Roy Chowdhury

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Daniel S W Tan

National Cancer Centre Singapore, Singapore

María Ochoa-de-Olza

Vall d`Hebron University Hospital, Barcelona, Spain

John Sarantopoulos

Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, USA

Ross A Soo

National University Cancer Institute, Singapore

Michela Maur

Oncologia Medica, AOU Policlinico di Modena, Modena, Emilia-Romagna, Italy

Barbara Deschler-Baier

Universitätsklinikum Würzburg, Wurzburg, Germany

Allen Lau

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Tanay S Samant

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Tyler Longmire

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Catherine A Sabatos-Peyton

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Radha Ramesh

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Tiancen Hu

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Ana Carion

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Padmaja Yerramilli-Rao

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Vasileios Askoxylakis

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA

Eunice L Kwak

Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA